Honkamp Krueger Financial Services Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,402 shares of the biopharmaceutical company’s stock after selling 702 shares during the period. Honkamp Krueger Financial Services Inc.’s holdings in Gilead Sciences were worth $611,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of GILD. Nuveen Asset Management LLC boosted its stake in Gilead Sciences by 1,208.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 9,847,359 shares of the biopharmaceutical company’s stock valued at $665,288,000 after purchasing an additional 9,094,586 shares during the last quarter. Marshall Wace North America L.P. boosted its stake in Gilead Sciences by 298.3% during the 2nd quarter. Marshall Wace North America L.P. now owns 3,418,196 shares of the biopharmaceutical company’s stock valued at $230,934,000 after purchasing an additional 2,559,972 shares during the last quarter. Parnassus Investments CA boosted its stake in Gilead Sciences by 13.3% during the 3rd quarter. Parnassus Investments CA now owns 10,133,261 shares of the biopharmaceutical company’s stock valued at $642,246,000 after purchasing an additional 1,187,424 shares during the last quarter. Nomura Holdings Inc. boosted its stake in Gilead Sciences by 5,205.6% during the 2nd quarter. Nomura Holdings Inc. now owns 946,882 shares of the biopharmaceutical company’s stock valued at $63,668,000 after purchasing an additional 929,035 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in Gilead Sciences by 23.5% during the 2nd quarter. Pictet Asset Management Ltd. now owns 4,378,155 shares of the biopharmaceutical company’s stock valued at $295,788,000 after purchasing an additional 832,194 shares during the last quarter. Institutional investors and hedge funds own 79.28% of the company’s stock.
In related news, EVP Brett A. Pletcher sold 15,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $66.85, for a total value of $1,002,750.00. Following the transaction, the executive vice president now directly owns 32,064 shares of the company’s stock, valued at approximately $2,143,478.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Brett A. Pletcher sold 5,677 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $63.31, for a total value of $359,410.87. Following the completion of the transaction, the executive vice president now directly owns 21,521 shares in the company, valued at $1,362,494.51. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 45,622 shares of company stock worth $2,986,438. 0.20% of the stock is owned by insiders.
Several brokerages have commented on GILD. Wells Fargo & Co set a $81.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Friday, October 25th. SunTrust Banks began coverage on Gilead Sciences in a report on Tuesday, November 12th. They set a “hold” rating and a $70.00 price target on the stock. Guggenheim set a $86.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Friday, October 25th. Cantor Fitzgerald lowered their price target on Gilead Sciences from $88.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, Oppenheimer raised Gilead Sciences from a “market perform” rating to an “outperform” rating in a report on Friday, January 3rd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $78.91.
Shares of Gilead Sciences stock opened at $64.10 on Thursday. Gilead Sciences, Inc. has a one year low of $60.89 and a one year high of $70.50. The stock’s fifty day moving average is $66.05 and its 200 day moving average is $65.25. The stock has a market cap of $81.22 billion, a P/E ratio of 10.06, a P/E/G ratio of 3.90 and a beta of 1.11. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.87 and a current ratio of 2.96.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 EPS for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. During the same period last year, the firm earned $1.84 EPS. Gilead Sciences’s revenue for the quarter was up .1% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 6.63 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, December 12th. This represents a $2.52 dividend on an annualized basis and a yield of 3.93%. Gilead Sciences’s dividend payout ratio is currently 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.